Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

2021133 citationsJournal Articlebronze Open Access

Authors

Sara M. Tolaney · Harvard University

Nabihah Tayob · Dana-Farber Cancer Institute

Chau T. Dang · Memorial Sloan Kettering Cancer Center

Denise A. Yardley · Sarah Cannon

Steven J. Isakoff · Massachusetts General Hospital

Vicente Valero · The University of Texas MD Anderson Cancer Center

Meredith Faggen

Abstract

Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Monoclonal and Polyclonal Antibodies Research

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 21, pp. 2375-2385

DOI: 10.1200/jco.20.03398

Field-Weighted Citation Impact: 9.83

Command Palette

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Authors

Abstract

Topics & Keywords

Publication Details